Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis

Journal of Diabetes and its Complications

Volumn 13, Issue 5-6, 1999, Pages 288-292

  Yun, Yong Seok ^a   Lee, Hyun Chul ^a   Park, Chong Seok ^a   Chang, Kyung Hee ^a   Cho, Chae Hwa ^a   Song, Young Duk ^a   Lim, Sung Kil ^a   Kim, Kyung Rae ^a   Huh, Kap Bum ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; OCTREOTIDE;

ACIDOSIS; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETONURIA; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETIC KETOACIDOSIS; FEMALE; HORMONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; KETONE BODIES; MALE; MIDDLE AGED; OCTREOTIDE; TIME FACTORS;

EID: 0033549926     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(99)00059-8     Document Type: Article

References (18)

1. Watchtel T.J., Tetu-Mouradjian L.M., Goldman D.L. Hyperosmolarity and acidosis in diabetes mellitus. A three-year experience in Rhode Island J Gen Intern Med. 6:1991;495-502.
2. Dobes R., Sakurai H., Sasaki H., Faloona G., Valverde J., Beatens D., Orci L., Unger R. Glucagon. Role in the hyperglycemia of diabetes mellitus Science. 187:1973;544-547.
3. Muller W.A., Faloona G.R., Unger R.H. Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance Am J Med. 54:1973;52-57.
4. Miles J.M., Gerich J.E. Glucose and ketone body kinetics in diabetic ketoacidosis. Clin Endocrinol Metab. 12:1983;303-319.
5. Kitabchi A.E., Ayyagari V., Guerra S.M.O. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann Intern Med. 84:1976;633-638.
6. Greco A.V., Ghirlanda G., Altomonte L., Manna R., Rebuzzi A.G., Bertoli A. Somatostatin and insulin infusion in the management of diabetic ketoacidosis. Horm Metab Res. 13:1981;310-314.
7. Spinas G., Bock A., Keller U. Reduced postprandial hyperglycemia after subcutaneous pump injection of somatostatin analogue (SMS 201-995) in insulin dependent diabetes mellitus. Diabetes Care. 8:1985;429-435.
8. Diem P., Robertson R.P. Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawl. Br J Clin Pharmacol. 32:1991;563-567.
9. Gerich J.E., Lorenzi M., Bier D.M. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med. 292:1975;985-989.
10. Guillemin R., Gerich J. Somatostatin. physiologic and clinical significance Ann Rev Med. 27:1976;379-388.
11. Falluca F., Barbetti F., Maldonato A., Spallone V., Giangrande L., Gambardella S. Effects of somatostatin on established induced ketosis. Horm Metabol Res. 14:1982;512-515.
12. Lundbaek K., Christensen S.E., Hansen A.A.P., Iversen J., Orskov H., Seyer-Hansen K. failure of somatostatin to correct manifest diabetic ketoacidosis. Lancet. 31:1976;215-218.
13. Bauer W., Briner U., Doepfner W. SMS 201-995; a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31:1982;1133-1140.
14. Plewe G., Nolken G., Krause U., Delpozo E., Beyer J. Somatostatin analogue SMS 201-995 in type 1 diabetes mellitus; initial experience after repeated administration. Scand J Gastroenterol Suppl. 119:1986;73-86.
15. Osei K., O'Dorisio T.M., Malarkey W.B., Craig E.L., Cataland S. Metabolic effects of long-acting somatostatin analogue (Sandostatin) in type 1 diabetic patients on conventional therapy. Diabetes. 38:1989;704-709.
16. Serrano-Rios M., Vanascues I., Saban J., Sevilla O.F., Del Pozo E. Somatostatin analogue SMS 201-995 and insulin needs in insulin dependent diabetic patients studied by means of artificial pancreas. J Clin Endocrinol Metab. 63:1986;1071-1074.
17. Barnes A.J., Long R.G., Adrian T.E. Effect of a long-acting octapeptide analogue of somatostatin on growth hormone and pancreatic and gastrointestinal hormones in man. Clin Sci. 61:1981;653-656.
18. Goodner C.J. Somatostatin leads to glucagon's renaissance. New Engl J Med. 292:1975;1022-1033.